Nuria Kotecki, MD

Medical Oncologist @Julesbordet Executive Officer for @oncodistinct « Always look on the bright side of life »

[Luca Arecco, MD @Lucarecco]

Proud to presenting primary translational results from the @oncodistinct #BrainStorm study at #ESMO25.
CSF ctDNA may serve as a reliable surrogate for CNS mutation profiles, complementing plasma ctDNA profiling.
Thanks to @nuriakb for this opportunity! @JulesBordet @OncoAlert

[Elisa Agostinetto @ElisaAgostinett]

At #ESMO25 @Lucarecco from @JulesBordet presents results from the Brainstorm study
CSF ctDNA in pts with brain and LM metastases had high mutational profile concordance with plasma and only partial overlap with extra-CNS tissue, while also uncovering CNS-specific mut
@OncoAlert

[Luca Arecco, MD @Lucarecco]

Thank you so much dear @ElisaAgostinett for highlight our presentation of the primary results from the BrainStorm study! @nuriakb @oncodistinct @JulesBordet @OncoAlert

[Mariana Brandao @MarianaBrandao0]

The large and dynamic @JulesBordet family at the @mybsmo Annual meeting at the beautiful city of Bruges 😍 thank you to @E_de_Azambuja & all the organization for such q wonderful Congress!! 🇧🇪
#BSMO25 #oncology

[Philippe Aftimos, MD  @aftimosp]

The stellar 💫 team of early-phase clinical trials investigators at @JulesBordet

@nuriakb @RitaSaudeConde @MarianaBrandao0

#ESMO24 #Women4Oncology #WomeninSTEM

[Anouk Goudsmit @AnoukGoudsmit]

The beautiful @JulesBordet family is reunited in Barcelona for the European Society of Medical Oncology annual meeting 2024 #ESMO24! We come back with the updates in oncology and lots of new projects to help our patients 💥🎗

[Cécilia GONDARD @ceciliagondard]

Le vote par Internet a démarré. Français du Benelux, mobilisez-vous!! Votez pour le Nouveau Front Populaire avec CECILIA GONDARD

[Oncodistinct Network @oncodistinct]

📢#ASCO2024 @BlancJeremy presented survival data from AURA trial: Avelumab as neoadjuvant therapy in patients with muscle-invasive urothelial carcinoma at ASCO2024 in Chicago,USA🇺🇸
🫱🏻‍🫲🏽Many thanks to all those who contributed to this trial.

[Rita Saúde Conde @RitaSaudeConde]

@nuriakb presenting first results from the Brainstorm Program : CSF-ctDNA as a Surrogate for Tumor Tissue DNA in BC patients with CNS Metastases 🧠🧬 @AACR @JulesBordet @oncodistinct
#bcbm #ctDNA #AACR24

[Oncodistinct Network @oncodistinct]

🆕🔊 First patient was recruited into the COPERNIC trial! A study from the OncoDistinct Network, aiming to evaluate the association between early changes of ctDNA and response to treatment in patients with advanced colorectal cancer. 🙌
#ColorectalCancer #ClinicalTrials #oncology

[Oncodistinct Network @oncodistinct]

💡 🔊 #ESMO23 Professor Ahmad Awada was the speaker of a session for Young Oncologists called : "Establishing successful global research collaborations and networks".
Thanks to @kevinpunie, the chair of this session.
#CancerResearch #ClinicalTrials #Collaboration #Network

[Anni Neumann @akndegarcia]

Great to see @kevinpunie chairing a session on @oncodistinct here at #ESMO23.
It's all about #collaboration ❤️

[Oncodistinct Network @oncodistinct]

OncoDistinct Team was at #ESMO2023 🇪🇦
○ Professor Ahmad Awada, one of the creators of this Network
○ Nuria Kotecki, executive officer of the OncoDistinct Network
○ Jacques Medioni, active member of the Network
○ Sofiane Bendiab, project coordinator of the OncoDistinct Network

[Nature Medicine @NatureMedicine]

BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.

Correspondence from @nuriakb @JulesBordet and colleagues

https://t.co/P7a5JJASaS

[Guilherme Nader Marta @GuiNaderMarta]

Brain metastases are still one of the biggest challenges in oncology

#BrainStorm is an international platform that gathers clinical, imaging & molecular data to inform better management strategies

Check it out on @NatureMedicine

👉 https://t.co/3uQCGK1qoI

@OncoAlert #bcsm

[Diogo Martins Branco @DMBranco]

📍#BrainStorm (NCT04109131), an investigator-initiated prospective #ClinicalStudy recruiting in 🇧🇪🇫🇷🇱🇺 to better understand #epidemio & #biology of 🧠 metastases

🗞 Hot off the press our correspondence to @NatureMedicine explaining design&objectives

👉https://t.co/yO5Rq4ZfIa 🧵

[Guilherme Nader Marta @GuiNaderMarta]

What is the best strategy after CDK4/6 inhibitors for the treatment of HR+ breast cancer?

We need high quality #RWE to address important questions that will not be answered by RCTs

@DMBranco presenting the #ALINE study proposal for the @oncodistinct network

@OncoAlert #bcsm

[Nuria Kotecki, MD @nuriakb]

@crisuarez08 and Marc Simó from #VHIO presenting an innovative study proposal in mRCC at the #Oncodistinct meeting.

[Diogo Martins Branco @DMBranco]

🔛 @RitaSaudeConde presenting to @oncodistinct the #SHAPERS trial funded by @KCETrials

Ph3 RCT of SCRT vs TNT in #older pts w/ locally advanced rectal cancer

@OncoAlert @JulesBordet

[Diogo Martins Branco @DMBranco]

🔛 @Nader_Guilherme discussing @oncodistinct the #LOCATOR trial proposal in implementation

Local ablative tx for pts w/ #oligometastatic HR+/HER2- #bcsm

@OncoAlert @JulesBordet